Literature DB >> 7585516

Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.

J He1, J J Olson, C D James.   

Abstract

In this study the expression of p16INK4, retinoblastoma protein (pRb), and cdk4 proteins have been examined in 18 malignant glioma cell lines and in 45 malignant glial tumors. Loss of p16INK4 expression associated with p16INK4 gene homozygous deletion was evident in 12 cell lines and in 10 primary tumors. Lack of p16INK4 expression was also evident in five tumors for which there was no evidence of p16INK4 gene homozygous deletion. Two of the cell lines and six of the primary tumors in which p16INK4 was present were determined to overexpress cdk4 in association with CDK4 gene amplification. Absence of pRb was determined in two of the cell lines and in ten of the tumors. In total, 16 of 18 cell lines and 25 of 45 tumors showed either a lack of p16INK4 or pRb or amplification-associated overexpression of cdk4. Two additional tumors showed an absence of pRb and p16INK4, and one tumor showed a lack of pRb combined with amplification-associated overexpression of cdk4. These results suggest a common growth-regulatory mechanism that is disrupted in gliomas by either suppressing the expression of p16INK4 or pRb or by increasing the expression of cdk4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585516

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

2.  p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB.

Authors:  G J Mulligan; J Wong; T Jacks
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

3.  Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression.

Authors:  Matthias Simon; Christian Simon; Gertraud Köster; Volkmar H J Hans; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

4.  Biologic tumor behavior in pilocytic astrocytomas.

Authors:  Muhittin Belirgen; Su Gulsun Berrak; Hilâl Ozdag; Suheyla Uyar Bozkurt; Emel Eksioglu-Demiralp; M Memet Ozek
Journal:  Childs Nerv Syst       Date:  2012-01-14       Impact factor: 1.475

Review 5.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 6.  The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth.

Authors:  S M Ivanchuk; S Mondal; P B Dirks; J T Rutka
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 7.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Pediatric glioblastomas: a histopathological and molecular genetic study.

Authors:  Vaishali Suri; Prasenjit Das; Pankaj Pathak; Ayushi Jain; Mehar Chand Sharma; Sachin Anil Borkar; Ashish Suri; Deepak Gupta; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2008-11-03       Impact factor: 12.300

Review 9.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

10.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.